Amy Kit Yu Fu

Amy Kit Yu Fu

Auto-generated profile, based on publicly available information

Amy Kit Yu Fu

Division of Life Science, State Key Laboratory of Nervous System Disorders, Daniel and Mayce Yu Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong Special Administrative Region, China

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AFAmy K. Y. Fu
Amy K. Y. Fu
KHKwok-Wang Hung
Kwok-Wang Hung
MYMichael Y. F. Yuen
Michael Y. F. Yuen
XZXiaopu Zhou
Xiaopu Zhou
DMDeejay S. Y. Mak
Deejay S. Y. Mak
NIN. Y. Ip
N. Y. Ip
Significance: Dysfunction of the innate immune system is involved in the pathogenesis of Alzheimer’s disease (AD); however, the pathophysiological mechanisms underlying these dysfunctions are unclear. Here we report that stimulation of IL-33/ST2 signaling rescues memory deficits and reduces the accumulation of β-amyloid in APP/PS1 mice that exhibit select pathologies associated with AD. Although impaired IL-33/ST2 signaling is associated with early progression of AD, IL-33 injection rescues contextual memory deficits and reduces the accumulation of β-amyloid in APP/PS1 mice. IL-33 skews the microglia toward an alternative activation state with enhanced Aβ phagocytic capacity and elevated antiinflammatory gene expression, which results in a decreased proinflammatory response in the brain. Thus, this study suggests that IL-33 can be developed as a new therapeutic intervention for AD.

3 December 2006 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
WFWing-Yu Fu
Wing-Yu Fu
YCYu Chen
Yu Chen
MSMustafa Sahin
Mustafa Sahin
XZXiao-Su Zhao
Xiao-Su Zhao
LSLei Shi
Lei Shi
NINancy Y Ip
Nancy Y Ip

23 June 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AFAmy K. Y. Fu
Amy K. Y. Fu
KHKwok-Wang Hung
Kwok-Wang Hung
HHHuiqian Huang
Huiqian Huang
SGShuo Gu
Shuo Gu
YSYang Shen
Yang Shen
NIN. Y. Ip
N. Y. Ip
Significance: Synaptic loss and dysfunction is associated with cognitive impairment in Alzheimer’s disease (AD). However, the pathophysiological mechanisms underlying synaptic impairment are largely unknown. Here, we reveal a previously unidentified signaling pathway whereby activation of a receptor tyrosine kinase EphA4 is critical for synaptic dysfunctions in AD. Proof-of-concept studies undertaken in both in vitro and in vivo systems demonstrate its importance in mediating the deficit of synaptic transmission and hippocampal long-term potentiation in AD models. Specifically, blocking the EphA4-dependent pathway through knockdown studies or the use of small-molecule inhibitors effectively rescues the impaired synaptic transmission induced by Aβ and reverses impaired synaptic plasticity in AD mouse models. Thus, this study reveals a new disease-modifying therapeutic intervention for AD.

18 May 2005 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ZGZhenglin Gu
Zhenglin Gu
QJQian Jiang
Qian Jiang
AFAmy K. Y. Fu
Amy K. Y. Fu
NINancy Y. Ip
Nancy Y. Ip
ZYZhen Yan
Zhen Yan
Recent linkage studies have identified a significant association of the neuregulin gene with schizophrenia, but how neuregulin is involved in schizophrenia is primarily unknown. Aberrant NMDA receptor functions have been implicated in the pathophysiology of schizophrenia. Therefore, we hypothesize that neuregulin, which is present in glutamatergic synaptic vesicles, may affect NMDA receptor functions via actions on its ErbB receptors enriched in postsynaptic densities, hence participating in emotional regulation and cognitive processes that are impaired in schizophrenia. To test this, we examined the regulation of NMDA receptor currents by neuregulin signaling pathways in prefrontal cortex (PFC), a prominent area affected in schizophrenia. We found that bath perfusion of neuregulin significantly reduced whole-cell NMDA receptor currents in acutely isolated and cultured PFC pyramidal neurons and decreased NMDA receptor-mediated EPSCs in PFC slices. The effect of neuregulin was mainly blocked by application of the ErbB receptor tyrosine kinase inhibitor, phospholipase C (PLC) inhibitor, IP3receptor (IP3R) antagonist, or Ca2+chelators. The neuregulin regulation of NMDA receptor currents was also markedly attenuated in cultured neurons transfected with mutant forms of Ras or a dominant-negative form of MEK1 (mitogen-activated protein kinase kinase 1). Moreover, the neuregulin effect was prevented by agents that stabilize or disrupt actin polymerization but not by agents that interfere with microtubule assembly. Furthermore, neuregulin treatment increased the abundance of internalized NMDA receptors in cultured PFC neurons, which was also sensitive to agents affecting actin cytoskeleton. Together, our study suggests that both PLC/IP3R/Ca2+and Ras/MEK/ERK (extracellular signal-regulated kinase) signaling pathways are involved in the neuregulin-induced reduction of NMDA receptor currents, which is likely through enhancing NR1 internalization via an actin-dependent mechanism.

1 May 2010 in Cell
Verified
Journal Article
Closed access
COChan-Yen Ou
Chan-Yen Ou
VPVivian Y. Poon
Vivian Y. Poon
CMCeline I. Maeder
Celine I. Maeder
SWShigeki Watanabe
Shigeki Watanabe
ELEmily K. Lehrman
Emily K. Lehrman
KSKang Shen
Kang Shen

26 December 2010 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
AFAmy K Y Fu
Amy K Y Fu
KHKwok-Wang Hung
Kwok-Wang Hung
WFWing-Yu Fu
Wing-Yu Fu
CSChong Shen
Chong Shen
YCYu Chen
Yu Chen
NINancy Y Ip
Nancy Y Ip